Labour 'must work' on Scots independence supporters The Scotsman
LABOUR must "engage" with voters who want Scottish independence and do more to make the argument for the Union, Tony Blair conceded yesterday.

Audio Medica - Medical Audio News Interviews & Podcasts search
another imatinib alternative, AMN 107, are also promising, as discussed by Like imatinib AMN 107 targets the BCR-ABL molecule, though with a different
Audio Medica - Medical Audio News Interviews & Podcasts search
AMN 107: Inhibitor of BCR-ABL Active in Imatinib Resistant Chronic Myeloid Like imatinib AMN 107 targets the BCR-ABL molecule, though with a different
Is AMN-107 a step forward from imatinib in the treatment of
The Philadelphia (Ph) chromosome was the first consistent chromosome abnormality identified in cance
An Open-Label, Multi-Center, Expanded Access Study of Oral AMN 107
An Open-Label, Multi-Center, Expanded Access Study of Oral AMN 107 in Adult Patients with Imatinib (Glivec®/ Gleevec®) - Resistant or - Intolerant Chronic
Investigational Drug Effective Against Imatinib-Resistant CML in
These two drugs or the AMN compound [AMN 107, a successor to imatinib in clinical development] still leave one back door, and that's this mutant T-315I,
AN OPEN-LABEL, MULTICENTER, EXPANDED ACCESS STUDY OF ORAL AMN 107
Study Summary Title:, AN OPEN-LABEL, MULTICENTER, EXPANDED ACCESS STUDY OF ORAL AMN 107 IN ADULT PATIENTS WITH IMATINIB (GLEEVEC) RESISTANT OR INTOLERANT
AMN 107 - The Leukemia & Lymphoma Society BBS
In the meantime, my doctor decided I would need a stem cell plant or one of the next drugs in cliincal trials such as AMN 107.
Clinical Trials
Expanded Access Program with AMN 107 for Patients with Imatinb -learn about the side effects that AMN 107 has on a patient and leukemia
Oncology Drug Research: Clinical Research Studies for Oncology
Learn about the clinical research study for our oncology drug. Research studies for Nilotinib (AMN107) are being conducted through our clinical trial
Nilotinib (AMN-107)
Nilotinib (AMN-107) for imatinib-resistant chronic myeloid Nilotinib (AMN-107) is an aminopyrimidine tyrosine kinase inhibitor that is administered amn+107: amn+107